Respiratory Drug Delivery

5th December to 6th December 2019,
London, United Kingdom

SMi are pleased to announce the launch of the Respiratory Drug Delivery conference as part of the newly branded Asthma and COPD series, which will be held in London on the 5th-6th December 2019.

With the rising prevalence of respiratory diseases such as Asthma, cystic fibrosis and COPD, this group of diseases are now amongst the leading cause death, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe, yet little work is being done to reduce this high mortality rate.

Opportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However, the unmet medical needs of respiratory disease sufferers remain.

Join us this year as SMi aim to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analyzing the success of digital medical devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design.

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

9:50 Analysing the challenges of Quality-by-Design in novel respiratory development

Herbert Wachtel, Senior Principal Scientist, Boehringer Ingelheim

• Considering all aspects of the drive towards highly novel devices and the accelerated launch of clone devices
• Determining the relationship between risk-based and knowledge-based approaches in showing understanding and control of the device design
• Assessing key concepts of design understanding, design robustness, manufacturing understanding and manufacturing robustness
• How to transition from a systematic approach, systematic approach of design of experiments, quality risk management and knowledge management through to predictive modelling and physical testing

• Evaluating the current drug delivery mechanism of dry powders inhalers (DPIs) and its effectiveness in delivery of fine drug particles deep into the lung airways
• Exploring the role of technology in DPI devices, including the development of battery powered external assistance
• Potentials to increase drug delivery to the lung and enabling regional lung targeting

12:20 Networking Lunch

13:20 Establishing the progress and challenges of Lung epithelial Nanoparticle uptake and drug delivery at the molecular level

Dr. Jorge Bernardino de la Serna (JbdlS) is a Senior Lecturer at the National Heart and Lung Institute, Imperial College London, and Visiting Scientist at the United Kingdom Research and Innovation. JBdlS has a markedly multidisciplinary research track record; he has ~25 publications in the last 5 years. JBdlS’s research has been highlighted on 6 journal covers for his work on protein-lipid localisation and dynamics; Tcell lipid-protein interactions in atopic dermatitis; advanced quantitative fluorescence microscopy and spectroscopy; and peptide/peptoid-protein interactions with biological films. All these publications had in common the employment of highly-advanced microscopy techniques. JBdlS last publication in ACSnano were he bserved the theragnostic effect in Gram Negative Bacteria of a fluorescent molecule at the nanoscale. This article has been highlighted in The Telegraph and BBC Sheffield. JBdlS has a track record of microscopy method development and customisation to understand molecular mechanisms in cell biology and in respiratory biophysics. He did his PhD at the University Complutense of Madrid in Respiratory Biophysics; then, moved to the University of Southern Denmark to employ advance imaging techniques to understand how pulmonary surfactant was impaired in knocked out animal models and in COPD patients. Later, after a short stage as visiting scientist at Prof. S. Hell, Nobel Laureate in Chemistry (2014) for the development of STED superresolution microscopy, JBdlS joined the University of Oxford. At the MRC Human Immunology Unit he investigated the mechanisms of early activation and synapse in T cells, developing cell compatible protein/lipid fluorescent labelling strategies and using quasi-single molecule microscopy. Later on, before the joined Imperial College London, he was recruited by the United Kingdom Research and Innovation to develop methods and techniques for the UK-based Scientific Community at the National Laboratory for Bioimaging in the UK.

• Identifying how nanoparticles are taken up at the alveolar barrier at the molecular level to help designing more site-specific and controlled drug delivery
• Assessing how nanoparticles can be the ideal delivery vehicle of therapeutic purposes to cells in vivo

14:00 Establishing a new way to increase the penetration rate of nanoparticles through pulmonary mucus by investigating the nanoparticle mucus interaction

• Rheology studies in human pulmonary mucus, what can we learn about the structure of mucus
• Stimulated emission depletion (STED) microscopy as a new method to visualize mucus structure
• Analyse the diffusion behaviour of nanoparticles in human pulmonary mucus at different temperatures
• Establishing a particle system which allows the contactless heating of PLGA-Nanoparticles

Chris Corrigan is Professor of Asthma, Allergy & Respiratory Science at King’s College London School of Medicine, based at Guy’s Hospital. He has published over 160 original manuscripts on the cellular and molecular immunopathology of asthma, and particularly phenotypes of severe and resistant disease, including aspirin-sensitive and non-atopic asthma, and received more than £20 million in peer reviewed research funding. He created the large adult allergy service, particularly the allergen immunotherapy service, and the severe asthma service based at Guy’s Hospital, recently commissioned by NHS England as one of the three national providers for care for patients suffering with severe asthma in Greater London. He is also deeply committed to undergraduate and postgraduate medical education. He currently sits on the Royal College of Physicians Specialist Advisory Committee on Allergy and in the past formulated the content of the SpR training programme in Adult Allergy now approved by the JRCPTB and the GMC. He is also Training Programme Director for Allergy in the London Deanery and is or has been educational supervisor to 12 Allergy SpRs, 10 PhD students and hundreds of medical undergraduates.

1. Over expression of the calcium sensing receptor on bronchial smooth muscle cells is responsible for the phenomenon of bronchial smooth muscle hyperresponsiveness in human asthma, a phenomenon which has never previously been explained mechanistically.
2. Many cationic products of inflammatory cells implicated in the airways inflammation frequently observed in human asthma, such as eosinophilic cationic proteins, are agonists of the calcium sensing receptor, providing the first ever, clear mechanistic link between airways inflammation and chronic airways narrowing in human asthma.
3. A variety of inhaled environmental agents urban particulate matter, allergens and respiratory viruses can activate epithelial and dendritic cells, causing local alarmin (IL-33, TSLP, IL-25) release and Th2 cytokine production by airways ILC2 and allergen=specific Th2 T cells. WE are accumulating evidence that the calcium sensing receptor antagonises these effects.
4. We are developing the technology to deliver micronised, re-purposed calcium sensing receptor antagonists (calcilytics) to human asthmatics by dry powder inhalation. We are planning a first in human study addressing the hypothesis that inhaled calcilytics abolish both the early- and late-phase responses in the classical, allergen bronchial challenge model in atopic asthma.
5. Calcilytics, by their effects in abolishing airways smooth muscle hyperresponsiveness and inflammation, are a clear candidate for the first non-steroidal replacement for both inhaled steroid and SABA/LABA therapy in the vast majority of asthmatics with mild/moderate disease.

15:20 Afternoon Tea

15:50 For more than three decades we’ve built more and apparently better inhalers – is it time for a new approach?

8:30 Registration & Coffee

9:00 Novel Approaches to characterise Aerosol Dynamics

Dr David A. Lewis is Director of Aerosol Research at Chiesi Limited, Chippenham UK. He holds a B.Sc. in Physics (1989) and M.Sc. and Ph.D. in Aerosol Science (1990 & 1994), from Essex University, England. He joined the Centre for Drug Formulation Studies at Bath University, England, in May 1996 to lead a start-up HFA programme sponsored by Chiesi Farmaceutici. The resultant successful development of HFA solution formulations lead to a rapid expansion of his group which transferred to Vectura in 1999 as a result of CDFS spin-out by the University of Bath. David joined Chiesi Limited in 2008 and established the UK Research Centre in Chippenham, UK which opened in July 2009.
David has authored over 170 research publications within the fields of pharmaceutics, analytical chemistry, and aerosol science. He is co-inventor of over 30 patents relating to inhaler formulations and devices. These inventions led to the Chiesi Modulite technology which has seen formulations of beclomethasone dipropionate, budesonide, formoterol and a beclomethasone dipropionate-formoterol combination becoming commercialized in several European countries.
Since establishing Chiesi’s UK Research Centre in 2008, David has allocated >£3M to support university collaborative research within the field of respiratory drug delivery. He is industrial supervisor for several PhD projects and is an Associate to Woolcock Medical Research Institute, University of Sydney, Australia

Setting the Scene: Introductory overview and case studies highlighting the reality of different characterisation approaches

10:30 Morning tea

• Assess the ability for remote photoplethysmographic (rPPG) technologies to solve the challenges of compliance in patient self monitoring
• Review the value of such technologies in predicting and preventing respiratory exacerbations
• Consider the barriers to adoption of mass rPPG monitoring
• Consider collaborations and partnerships for future delivery

12:30 Networking Lunch

13:30 Respiratory drug delivery: what may the future hold?

Mayur is a registered Clinical Scientist - a regulated professional qualification required to advise safety and effectiveness of medical devices/ physiological measurement techniques in the NHS, UK.
His expertise lies in guiding Pharma and medical device companies to devise commercially focussed development plans for innovative devices and technologies by integrating regulatory aspects with the commercial and technical needs. He has led a number of turnkey development projects. His skills span across business, design, development, regulatory, quality, human factors and commercialisation.
Mayur also lectures King’s College London postgraduate students and trainee clinical scientists on a range of medical device and healthcare management subjects.

Setting the scene for how intelligent drug delivery can transform the field of respiration

15:00 Afternoon Tea

15:30 Close of Day Two

FEATURED SPEAKERS

Dr David A. Lewis is Director of Aerosol Research at Chiesi Limited, Chippenham UK. He holds a B.Sc. in Physics (1989) and M.Sc. and Ph.D. in Aerosol Science (1990 & 1994), from Essex University, England. He joined the Centre for Drug Formulation Studies at Bath University, England, in May 1996 to lead a start-up HFA programme sponsored by Chiesi Farmaceutici. The resultant successful development of HFA solution formulations lead to a rapid expansion of his group which transferred to Vectura in 1999 as a result of CDFS spin-out by the University of Bath. David joined Chiesi Limited in 2008 and established the UK Research Centre in Chippenham, UK which opened in July 2009.
David has authored over 170 research publications within the fields of pharmaceutics, analytical chemistry, and aerosol science. He is co-inventor of over 30 patents relating to inhaler formulations and devices. These inventions led to the Chiesi Modulite technology which has seen formulations of beclomethasone dipropionate, budesonide, formoterol and a beclomethasone dipropionate-formoterol combination becoming commercialized in several European countries.
Since establishing Chiesi’s UK Research Centre in 2008, David has allocated >£3M to support university collaborative research within the field of respiratory drug delivery. He is industrial supervisor for several PhD projects and is an Associate to Woolcock Medical Research Institute, University of Sydney, Australia

Senior Lecturer, Inhalation, Toxicology and Pharmacology, Imperial College London

Dr. Jorge Bernardino de la Serna (JbdlS) is a Senior Lecturer at the National Heart and Lung Institute, Imperial College London, and Visiting Scientist at the United Kingdom Research and Innovation. JBdlS has a markedly multidisciplinary research track record; he has ~25 publications in the last 5 years. JBdlS’s research has been highlighted on 6 journal covers for his work on protein-lipid localisation and dynamics; Tcell lipid-protein interactions in atopic dermatitis; advanced quantitative fluorescence microscopy and spectroscopy; and peptide/peptoid-protein interactions with biological films. All these publications had in common the employment of highly-advanced microscopy techniques. JBdlS last publication in ACSnano were he bserved the theragnostic effect in Gram Negative Bacteria of a fluorescent molecule at the nanoscale. This article has been highlighted in The Telegraph and BBC Sheffield. JBdlS has a track record of microscopy method development and customisation to understand molecular mechanisms in cell biology and in respiratory biophysics. He did his PhD at the University Complutense of Madrid in Respiratory Biophysics; then, moved to the University of Southern Denmark to employ advance imaging techniques to understand how pulmonary surfactant was impaired in knocked out animal models and in COPD patients. Later, after a short stage as visiting scientist at Prof. S. Hell, Nobel Laureate in Chemistry (2014) for the development of STED superresolution microscopy, JBdlS joined the University of Oxford. At the MRC Human Immunology Unit he investigated the mechanisms of early activation and synapse in T cells, developing cell compatible protein/lipid fluorescent labelling strategies and using quasi-single molecule microscopy. Later on, before the joined Imperial College London, he was recruited by the United Kingdom Research and Innovation to develop methods and techniques for the UK-based Scientific Community at the National Laboratory for Bioimaging in the UK.

Aljoscha Koenneke

PhD Pharmacist, Institute of Biopharmaceutics and Pharmaceutical Technology, Saarland University

Chris Corrigan

Professor of Asthma, Allergy and Immunology, Kings College London

Chris Corrigan is Professor of Asthma, Allergy & Respiratory Science at King’s College London School of Medicine, based at Guy’s Hospital. He has published over 160 original manuscripts on the cellular and molecular immunopathology of asthma, and particularly phenotypes of severe and resistant disease, including aspirin-sensitive and non-atopic asthma, and received more than £20 million in peer reviewed research funding. He created the large adult allergy service, particularly the allergen immunotherapy service, and the severe asthma service based at Guy’s Hospital, recently commissioned by NHS England as one of the three national providers for care for patients suffering with severe asthma in Greater London. He is also deeply committed to undergraduate and postgraduate medical education. He currently sits on the Royal College of Physicians Specialist Advisory Committee on Allergy and in the past formulated the content of the SpR training programme in Adult Allergy now approved by the JRCPTB and the GMC. He is also Training Programme Director for Allergy in the London Deanery and is or has been educational supervisor to 12 Allergy SpRs, 10 PhD students and hundreds of medical undergraduates.

Chris Corrigan

Professor of Asthma, Allergy and Immunology, Kings College London

Dave Lewis

Aerosol Science Director, Chiesi Ltd

Dr David A. Lewis is Director of Aerosol Research at Chiesi Limited, Chippenham UK. He holds a B.Sc. in Physics (1989) and M.Sc. and Ph.D. in Aerosol Science (1990 & 1994), from Essex University, England. He joined the Centre for Drug Formulation Studies at Bath University, England, in May 1996 to lead a start-up HFA programme sponsored by Chiesi Farmaceutici. The resultant successful development of HFA solution formulations lead to a rapid expansion of his group which transferred to Vectura in 1999 as a result of CDFS spin-out by the University of Bath. David joined Chiesi Limited in 2008 and established the UK Research Centre in Chippenham, UK which opened in July 2009.
David has authored over 170 research publications within the fields of pharmaceutics, analytical chemistry, and aerosol science. He is co-inventor of over 30 patents relating to inhaler formulations and devices. These inventions led to the Chiesi Modulite technology which has seen formulations of beclomethasone dipropionate, budesonide, formoterol and a beclomethasone dipropionate-formoterol combination becoming commercialized in several European countries.
Since establishing Chiesi’s UK Research Centre in 2008, David has allocated >£3M to support university collaborative research within the field of respiratory drug delivery. He is industrial supervisor for several PhD projects and is an Associate to Woolcock Medical Research Institute, University of Sydney, Australia

Gunilla Petersson

Science and Innovation Director, Astrazeneca

Herbert Wachtel

Senior Principal Scientist, Boehringer Ingelheim

Jorge Bernardino de le Sarna

Senior Lecturer, Inhalation, Toxicology and Pharmacology, Imperial College London

Dr. Jorge Bernardino de la Serna (JbdlS) is a Senior Lecturer at the National Heart and Lung Institute, Imperial College London, and Visiting Scientist at the United Kingdom Research and Innovation. JBdlS has a markedly multidisciplinary research track record; he has ~25 publications in the last 5 years. JBdlS’s research has been highlighted on 6 journal covers for his work on protein-lipid localisation and dynamics; Tcell lipid-protein interactions in atopic dermatitis; advanced quantitative fluorescence microscopy and spectroscopy; and peptide/peptoid-protein interactions with biological films. All these publications had in common the employment of highly-advanced microscopy techniques. JBdlS last publication in ACSnano were he bserved the theragnostic effect in Gram Negative Bacteria of a fluorescent molecule at the nanoscale. This article has been highlighted in The Telegraph and BBC Sheffield. JBdlS has a track record of microscopy method development and customisation to understand molecular mechanisms in cell biology and in respiratory biophysics. He did his PhD at the University Complutense of Madrid in Respiratory Biophysics; then, moved to the University of Southern Denmark to employ advance imaging techniques to understand how pulmonary surfactant was impaired in knocked out animal models and in COPD patients. Later, after a short stage as visiting scientist at Prof. S. Hell, Nobel Laureate in Chemistry (2014) for the development of STED superresolution microscopy, JBdlS joined the University of Oxford. At the MRC Human Immunology Unit he investigated the mechanisms of early activation and synapse in T cells, developing cell compatible protein/lipid fluorescent labelling strategies and using quasi-single molecule microscopy. Later on, before the joined Imperial College London, he was recruited by the United Kingdom Research and Innovation to develop methods and techniques for the UK-based Scientific Community at the National Laboratory for Bioimaging in the UK.

Laurence Pearce

CEO, Xim Ltd

Mark Milton-Edwards

Mayur Patel

Mayur is a registered Clinical Scientist - a regulated professional qualification required to advise safety and effectiveness of medical devices/ physiological measurement techniques in the NHS, UK.
His expertise lies in guiding Pharma and medical device companies to devise commercially focussed development plans for innovative devices and technologies by integrating regulatory aspects with the commercial and technical needs. He has led a number of turnkey development projects. His skills span across business, design, development, regulatory, quality, human factors and commercialisation.
Mayur also lectures King’s College London postgraduate students and trainee clinical scientists on a range of medical device and healthcare management subjects.

Orla Ni Ogain

Richard Marsden

CEO , Synairgen Ltd

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

Tim Higenbottam

President of the Faculty of Pharmaceutical Medicine , Faculty of Pharmaceutical Medicine

Official Media Partner

View detailsONdrugDelivery MagazineOfficial Media Partnerhttp://ondrugdelivery.comONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

Supporting Media Partners

View detailsIPI Supporting Media Partnershttp://www.ipimediaworld.comIPI – International Pharmaceutical Industry
Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.

View detailsMednousSupporting Media Partnershttp://www.MedNous.comMedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

View detailsPharma Journalist Supporting Media Partnershttp://www.pharmajournalist.comPharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.
Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

View detailsPharmaceutical TechnologySupporting Media Partnershttp://www.pharmaceutical-technology.comPharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

View detailsPharmalicensingSupporting Media Partnershttp://www.pharmalicensing.comPharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc

View detailspharmanews hqSupporting Media Partnershttp://http://pharmanewshq.comMedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues.
Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

View detailspharmaphorumSupporting Media Partnershttp://www.pharmaphorum.compharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

View detailsTechnology NetworksSupporting Media Partnershttp://go.technologynetworks.com/subscribe-to-newslettersFounded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.

SPEAKER INTERVIEW WITH RICHARD MARSDEN, Synairgen Ltd

Respiratory Drug Delivery Speaker bio's 2019

Respiratory Drug Delivery Programme 2019

Media Partners

ONdrugDelivery Magazine

ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

Media Partners

Pharmalicensing

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc

Technology Networks

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

IPI

IPI – International Pharmaceutical Industry
Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.

Mednous

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

pharmaphorum

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

World Pharma News

pharmanews hq

MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues.
Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.
Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Pharmaceutical Technology

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

SAVE TO

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

Cookie Policy

From May 2011 a new privacy law came into effect across the EU. The law requires
that websites ask visitors for consent to use most web cookies. We use cookies to
ensure you get the best experience on our website –Tick here to accept cookie use
Details of our cookie use may be found here.

WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy,
which maintains that in order to be effective, learning should be organised and
structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional
competence’

CPD is a common requirement of individual membership with professional bodies and
Institutes. Increasingly, employers also expect their staff to undertake regular
CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do
not become obsolete, and allows for best practice and professional standards to
be upheld.

CPD can be undertaken through a variety of learning activities including instructor
led training courses, seminars and conferences, e:learning modules or structured
reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with
a collective membership of circa 4 million professionals, and they all expect their
members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked
to a licence to practice, for others it’s obligatory. By ensuring that their members
undertake CPD, the professional bodies seek to ensure that professional standards,
legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide
online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’
or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve
within a given time period. These schemes can also use different ‘currencies’ such
as points, merits, units or credits, where an individual must accumulate the number
required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of
learning.

‘Output’ based schemes are learner centred. They require individuals to set learning
goals that align to professional competencies, or personal development objectives.
These schemes also list different ways to achieve the learning goals e.g. training
courses, seminars or e:learning, which enables an individual to complete their CPD
through their preferred mode of learning.

As a formal provider of CPD certified activities, SMI Group can provide an indication
of the learning benefit gained and the typical completion. However, it is ultimately
the responsibility of the delegate to evaluate their learning, and record it correctly
in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces
and looking to the UK to benchmark educational standards. The undertaking of CPD
is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk